Larimar Therapeutics Inc (LRMR)

Larimar Therapeutics Inc (LRMR) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $224M; returns 1 day +3.5%, 1 week +18.4%, 1 year -40.5%.

Larimar Therapeutics Inc. (LRMR) is a clinical-stage biotechnology company primarily focused on developing novel treatments for complex rare diseases. The company's core business revolves around its lead product candidate, nomlabofusp (formerly CTI-1601), which is being developed as a potential disease-modifying therapy for Friedreich's ataxia (FA), a severe and progressive genetic disorder.

Groups LRMR belongs to

• Biotechnology
• Clinical Stage Biotech
• Rare Diseases
• Biopharmaceutical
• Healthcare
• Life Sciences
• Biologics
• Clinical Stage
• R&D

LRMR financial model: income statement, cash flow and balance sheet